Cart
sales@molnova.com
SRX3177
CAS No. 2241237-51-2
SRX3177( —— )
Catalog No. M36306 CAS No. 2241237-51-2
SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 208 | In Stock |
|
| 5MG | 160 | In Stock |
|
| 10MG | 240 | In Stock |
|
| 25MG | 408 | In Stock |
|
| 50MG | 550 | In Stock |
|
| 100MG | 784 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSRX3177
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
-
DescriptionSRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ), <2.5 nM (CDK4), 3.3 nM (CDK6), respectively. SRX3177 exerts broad cytotoxic activity against cancer cells, but acts friendly with normal epithelial cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain | PI3K | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241237-51-2
-
Formula Weight584.69
-
Molecular FormulaC31H32N6O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (42.76 mM; Ultrasonic )
-
SMILESC(N(C)C)(=O)C=1N(C=2C(C1)=CN=C(NC3=CC=C(C=C3)C=4C5=C(SC4)C(=O)C=C(O5)N6CCOCC6)N2)C7CCCC7
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Burgoyne AM, et al. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020 Jul 28;6(1):49.?
molnova catalog
related products
-
PBRM1-BD2-IN-8
PBRM1-BD2-IN-8 (compound 34) is a potent PBRM1 Bromodomain inhibitor with PBRM1-BD2 Kd of 4.4 μM, PBRM1-BD2 IC50 of 0.16 μM, and PBRM1-BD5 Kd of 25 μM; PBRM1-BD2-IN-8 shows anti-cancer activity.
-
Menin-MLL inhibitor ...
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6).
-
Molibresib besylate
Molibresib besylate (GSK 525762C) is a selective and potent inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential anticancer activity for the study of refractory hematologic malignant diseases.
